StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Madrigal Pharmaceuticals's total debt was $340.79M at Jun 30, 2026. For fiscal 2025 it was $339.88M, up 189.1% from the year before. The highest annual figure on record is $339.88M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$339.88M+189.1%
FY2024Dec 31, 2024$117.57M+1.8%
FY2023Dec 31, 2023$115.48M+134.3%
FY2022Dec 31, 2022$49.29M–
FY2021Dec 31, 2021$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$340.79M+187.9%
Q1 FY2026Mar 31, 2026$340.33M+188.4%
Q4 FY2025Dec 31, 2025$339.88M+189.1%
Q3 FY2025Sep 30, 2025$339.75M+190.2%
Q2 FY2025Jun 30, 2025$118.38M+1.5%
Q1 FY2025Mar 31, 2025$118.01M+1.6%
Q4 FY2024Dec 31, 2024$117.57M+1.8%
Q3 FY2024Sep 30, 2024$117.09M+2.1%
Q2 FY2024Jun 30, 2024$116.61M+17.5%
Q1 FY2024Mar 31, 2024$116.14M+38.3%
Q4 FY2023Dec 31, 2023$115.48M+134.3%
Q3 FY2023Sep 30, 2023$114.73M+134.2%
Q2 FY2023Jun 30, 2023$99.25M+103.9%
Q1 FY2023Mar 31, 2023$83.97M–
Q4 FY2022Dec 31, 2022$49.29M–
Q3 FY2022Sep 30, 2022$48.98M–
Q2 FY2022Jun 30, 2022$48.67M–
Q4 FY2021Dec 31, 2021$0–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?